Partner Judy Waltz was quoted in a Modern Healthcare article, “Feds Will Appeal Loss in Medicare Fraud Case Over Hospice Eligibility,” on May 27, 2016. The article discussed the federal government’s appeal of a ruling in a health care fraud case involving hospice care provider AseraCare and disagreements between doctors over patients’ eligibility for hospice care. Waltz said the appeal by the government isn’t surprising, and said if the appeals court rules against AseraCare, it could be an issue for hospices and other providers. She was quoted saying, “I agree that an unsupported diagnosis or assessment isn’t appropriate but if there’s documentation that supports the decision, then I think there really needs to be … a real deference to the treating physician or attending physician, the person who’s actually there.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”